We have an updated report [Version - 2023] available. Kindly sign up to get the sample of the report.

Global Psoriasis Pipeline Drugs Market Assessment: Industry Analysis, Pipeline Review, Clinical Trials, Market Potential - Forecast to 2023

Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Executive Summary

The report titled "Global Psoriasis Pipeline Drugs Market Assessment: Industry Analysis, Pipeline Review, Clinical Trials, Market Potential - Forecast to 2023" presents the market potential of six major pipeline drugs meant for the treatment of Psoriasis. These six drugs that fall in the various categories of Injectables, Oral pills and Topical creams/lotions by mode of administration have been recognized as being clinically effective in Psoriasis treatment. Expected to be launched in the market within the next 4-5 years, these six potential drugs are likely to bring about major changes in the way psoriasis is treated globally.

A comprehensive research report created through extensive primary research (inputs from industry experts, companies, stakeholders) and secondary research, the report aims to present the analysis of Global Psoriasis Pipeline Drugs Market by assessing the potential of the six drugs that will be launched in the near future. Also, the report assesses the results of various clinical trials undertaken for each of the six drugs, the product profile, description and regulatory phase of each of the six drugs. Also, 7Ps Analysis (Patent, Phase, Pathway, Patient, Physician, Payer, Partner) has been done for each of the six drugs to present the current perspective.

Over the recent years, the Psoriasis Drugs market is growing rapidly due to rising prevalence of Psoriasis patients around the world. Globally, the growth of Psoriasis Drugs market is driven by rising psoriatic population. The global psoriasis drugs market is projected to display a robust growth during 2019- 2023, chiefly driven by low efficacy and tolerability of present psoriasis drugs and improved safety and efficacy of investigational drugs.

The report has covered and analysed the major psoriasis drugs that are in pipeline and expected to be launched in the near future. The product profile, assessment of clinical trials, the regulatory phases and the potential of the drugs has been analysed in the report. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decision. The report titled "Global Psoriasis Pipeline Drugs Market Assessment: Industry Analysis, Pipeline Review, Clinical Trials, Market Potential - Forecast to 2023" also analyzes the incidences of psoriasis in countries like United States, United Kingdom, France, Italy, Spain, Germany and Norway.


Scope of the Report

Psoriasis Pipeline Drugs Assessment - Drug X1, X2, X3, X4, X5, X6 (Forecast Period: 2019-2023)
• Market Potential
• Clinical Trials
• Product Description
• Regulatory Phases
• 7Ps Analysis

Country Analysis - US, UK, France, Italy, Spain, Germany and Norway (Forecast Period: 2019-2023)
• Incidence of Psoriasis

Other Report Highlights
• Company Analysis - UCB, Sun Pharmaceutical Industries Ltd, Boehringer Ingelheim, Forward Pharma, Almirall and Valeant Pharmaceuticals

Customization of the Report
The report could be customized according to the client's specific research requirements. No additional cost will be required to pay for limited additional research.

Table of Contents

1. Research Methodology

2. Psoriasis - An Overview
2.1. Symptoms of Psoriasis
2.2. Types of Psoriasis
2.3. Causes of Psoriasis
2.4. Triggers, Risk Factors and Complications of Psoriasis

3. Diagnosis of Psoriasis

4. Treatment of Psoriasis

5. Anti-Psoriasis Pipeline Drugs

5.1. Anti-Psoriasis Pipeline Drugs - Cimzia (Certolizumab Pegol)
5.1.1. Description
5.1.2. Regulatory Milestones
5.1.3. Advantages & Disadvantages
5.1.4. Product Profile & Launch Date
5.1.5. Clinical Trials and Status
5.1.6. Pivotal Clinical Trials and Results
5.1.7. Cimzia (Certolizumab Pegol) - Global Market Potential
5.1.8. Cimzia (Certolizumab Pegol) - 7Ps Analysis

5.2. Anti-Psoriasis Pipeline Drugs - Tildrakizumab (MK-3222)
5.2.1. Description
5.2.2. Regulatory Milestones
5.2.3. Advantages & Disadvantages
5.2.4. Product Profile & Launch Date
5.2.5. Clinical Trials and Status
5.2.6. Pivotal Clinical Trials and Results
5.2.7. Tildrakizumab (MK-3222)- Global Market Potential
5.2.8. Tildrakizumab (MK-3222)- 7Ps Analysis

5.3. Anti-Psoriasis Pipeline Drugs - Risankizumab (BI 655066)
5.3.1. Description
5.3.2. Regulatory Milestones
5.3.3. Advantages & Disadvantages
5.3.4. Product Profile & Launch Date
5.3.5. Clinical Trials and Status
5.3.6. Pivotal Clinical Trials and Results
5.3.7. Risankizumab (BI 655066)- Global Market Potential
5.3.8. Risankizumab (BI 655066)- 7Ps Analysis

5.4. Anti-Psoriasis Pipeline Drugs - FP187
5.4.1. Description
5.4.2. Regulatory Milestones
5.4.3. Advantages & Disadvantages
5.4.4. Product Profile & Launch Date
5.4.5. Clinical Trials and Status
5.4.6. Pivotal Clinical Trials and Results
5.4.7. FP187 - Global Market Potential
5.4.8. FP187 - 7Ps Analysis

5.5. Anti-Psoriasis Pipeline Drugs - Skilarence (LAS41008)
5.5.1. Description
5.5.2. Regulatory Milestones
5.5.3. Advantages & Disadvantages
5.5.4. Product Profile & Launch Date
5.5.5. Clinical Trials and Status
5.5.6. Pivotal Clinical Trials and Results
5.5.7. Skilarence (LAS41008) - Global Market Potential
5.5.8. Skilarence (LAS41008) - 7Ps Analysis

5.6. Anti-Psoriasis Pipeline Drugs - Duobrii (IDB 118)
5.6.1. Description
5.6.2. Regulatory Milestones
5.6.3. Advantages & Disadvantages
5.6.4. Product Profile & Launch Date
5.6.5. Clinical Trials and Status
5.6.6. Pivotal Clinical Trials and Results
5.6.7. Duobrii (IDB 118) - Global Market Potential
5.6.8. Duobrii (IDB 118) - 7Ps Analysis

6. Company Profiles
6.1. UCB
6.2. Sun Pharmaceutical Industries Ltd
6.3. Boehringer Ingelheim
6.4. Forward Pharma
6.5. Almirall
6.6. Valeant Pharmaceuticals 

7. Number of Psoriasis Patients By Country
7.1. U.S
7.2. U.K
7.3. France
7.4. Italy
7.5. Germany
7.6. Norway

Choose License Type

Happy To Assist You

Contact Images

We will be happy to help you find what you need. Please call us or write to us:

Frequently Asked Questions

This report incorporates the analysis of factors that augments the market growth. Report presents competitive landscape of the global market. This also provides the scope of different segments and applications that can potentially influence the market in the future. The analysis is based on current market trends and historic growth data. It includes detailed market segmentation, regional analysis, and competitive landscape of the industry.
The report efficiently evaluates the current market size and provides industry forecast. The market was valued at xxx Million US$ in 2019, and is expected to grow at a CAGR of xx% during the period 2020-2027.
The report efficiently evaluates the current market size and provides forecast for the industry in terms of Value (US$ Mn) and Volume (Thousands Units).
Market is segmented by:
  • Product Types
  • Drug Class
  • Indication
  • Applications
  • Services Types
  • End-users
  • Distribution channel
  • Regions
The report share key insights on the following:
  • Current market size
  • Market forecast
  • Market opportunities
  • Key drivers
  • Restraints
  • Pipeline Analysis
  • Incidence Rate
  • Epidemiology Analysis
  • Prevalence rate
  • Regulatory scenario
  • Industry trend
  • Pestle Analysis
  • Porter’s Analysis
  • New product approvals/launch
  • Promotion and marketing initiatives
  • Pricing analysis
  • Export-import analysis
  • Trade analysis
  • Competitive landscape
It helps the businesses in making investments decisions.
Customization helps the organization to gain insight on specific segments and regions of interest. Thus, WMR offers tailored report information based on business requirement in order to take strategic calls.
Contact us

mapicon
Sales Office (U.S.):
Worldwide Market Reports, 533 Airport Boulevard, Suite 400, Burlingame, CA 94010, United States

mapicon+1-415-871-0703

mapicon
Asia Pacific Intelligence Center (India):
Worldwide Market Reports, 403, 4th Floor, Bremen Business Center, Aundh, Pune, Maharashtra 411007, India.

Newsletter

Want us to send you latest updates of the current trends, insights, and more, signup to our newsletter (for alerts, special offers, and discounts).


Secure Payment By:
paymenticon

This website is secured Origin CA certificate on the server, Comodo, Firewall and Verified Sitelock Malware Protection

secureimg

© 2024 Worldwide Market Reports. All Rights Reserved